Plexus Ventures
Plexus
We help companies identify, evaluate, and negotiate in-licensing opportunities to expand their growth potential and geographic presence.
We advise companies in developing an out-licensing strategy and guide them in maximizing the value of their compounds, products, and technologies.
We help firms identify potential product and company acquisitions, develop deal structures, and negotiate definitive agreements.
We are global experts in pharmaceutical divestments, working with companies to target buyers, generate competition for assets, and maximize proceeds.
GLOBAL PRESENCE world

1-888-PLEXUS0 (753-9870)

info@plexusventures.com
RECENT NEWS
  • April 28, 2010 Plexus Ventures to Support Novartis US in Business Development
  • April 27, 2010 Richard Brown of Plexus Ventures to Participate in 2010 BIO International Convention
  • April 8, 2010 Plexus Ventures to Assist GlaxoSmithKline with Product Divestments
  • April 7, 2010 Plexus Ventures Launches Custom Business Development Services to Augment Clients' Internal Expertise
PharmaTimes World News
  • July 29, 2010Strong quarter for AstraZeneca as FDA panel backs Brilinta
  • July 29, 2010Solid results at Sanofi, plays down Genzyme bid
  • July 29, 2010Bayer pharma earnings fall as R&D spend climbs
  • July 28, 2010US patients “should have EU-approved drugs”
  • July 28, 2010Servier could be hit with hefty fine for ‘misleading’ EU
Home | About | Services | Track Record | News Room | Contact | Japanese Japanese Language
  • Overview
  • Our Approach
  • Our History
  • Our Team
  • Our Offices
  • Overview
  • In-Licensing
  • Out-Licensing
  • Acquisitions
  • Divestments
  • Overview
  • Case Studies
  • Client List
  • Press Releases
  • Articles & Presentations
  • Media Inquiries